Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Posaconazole delayed-release tablets (adult prophylaxis) - selected U.S. labeling
Product / population
Adults receiving fungal prophylaxis with whole oral 100 mg delayed-release posaconazole tablets. The selected generic label is prophylaxis-only; oral suspension, PowderMix and IV formulations are excluded.
Renal method
eGFR mL/min/1.73 m2 for exposure-monitoring caution, not a reduced-dose algorithm.
Source revision
Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved
2026-09-05
Local review status
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Official
Posaconazole delayed-release tablets (adult prophylaxis) - selected U.S. labeling
U.S. product labeling / DailyMed · Adults receiving fungal prophylaxis with whole oral 100 mg delayed-release posaconazole tablets. The selected generic label is prophylaxis-only; oral suspension, PowderMix and IV formulations are excluded.
Renal method: eGFR mL/min/1.73 m2 for exposure-monitoring caution, not a reduced-dose algorithm. Source date: Label revision date not separately recorded; retrieval date is not the revision date. Retrieved: 2026-09-05
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Labeled basic dosing
For prophylaxis of invasive Aspergillus/Candida infections in severely immunocompromised adults: 300 mg orally twice on day 1, then 300 mg once daily from day 2. Duration follows recovery from neutropenia or immunosuppression. Swallow tablets whole.
The label keeps the same dosing in renal impairment. At eGFR below 20 mL/min/1.73 m2, monitor especially closely for breakthrough fungal infection because exposure is variable. Hemodialysis does not remove posaconazole.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.